• SNS-032 (BMS-387032) in Cancer Assays

  2026-08-20

  SNS-032 (BMS-387032) combines potent CDK9 activity with CDK2 and CDK7 inhibition, enabling linked studies of transcription, cell-cycle control, viability, and apoptosis. This practical guide shows how to build concentration–time workflows, interpret RNA polymerase II phosphorylation, and assess where findings from host-factor virology can—and cannot—extend cancer research.

• Cy5-UTP: From RNA Labeling to Trafficking Readouts

  2026-08-19

  Cy5-UTP enables direct fluorescent RNA probe synthesis while revealing how assay design can separate RNA production, detection, and intracellular trafficking. This article connects Cyanine 5-uridine triphosphate workflows with recent mechanistic evidence on lipid nanoparticle transport.

• GANT61 GLI Inhibitor Workflow for Tumor Models

  2026-08-19

  GANT61 enables direct interrogation of GLI1/GLI2 output in cancer cells, xenografts, and tumor–immune co-culture systems. This workflow connects practical dosing and solvent handling with the emerging biology of GLI2-driven WNT, prostaglandin, and immunotherapy resistance.

• Acetoacetic Acid Sodium Salt for Cell Assays

  2026-08-18

  This scenario-driven guide explains how Acetoacetic acid sodium salt (SKU A9940) can improve control of metabolic confounders in cell viability, proliferation, and cytotoxicity workflows. It covers stock preparation, assay compatibility, interpretation, and evidence-based product selection.

• AZD1390: ATM Kinase Inhibitor Workflows

  2026-08-18

  AZD1390 provides a high-potency, selective way to interrogate ATM-dependent DNA damage response signaling, with practical value in radiation, cell-cycle, and replication-stress assays. This workflow-focused guide connects glioblastoma and lung cancer radiosensitization with emerging REV1–DHX36–G-quadruplex biology while emphasizing controls, dosing logic, and troubleshooting.

• Aging Lens Epithelium and Ferroptosis

  2026-08-17

  Wei and colleagues identify lens epithelial cells as an age-sensitized ferroptosis model, linking cataract-associated oxidative imbalance with vulnerability to system Xc⁻ and GPX4 inhibition. Their combination of human cell, mouse ex vivo, glutathione-depletion, and transcriptomic experiments provides a framework for studying redox and iron homeostasis in lens aging while defining limits for extrapolation to cancer models.

• Spatial Lipid Metabolomics and POCD

  2026-08-16

  The reference study maps hippocampal lipid abnormalities in a rat cardiopulmonary bypass model of postoperative cognitive dysfunction, linking CA1 lipid accumulation with altered iPLA2 and SPT signals and synaptic ultrastructural damage. Its DHA- and myriocin-based intervention provides evidence that correcting lipid metabolic imbalance may reduce cognitive vulnerability after surgery, while leaving important questions about molecular specificity and clinical translation.

• ER Stress, GRP78/ATF6/CHOP, and Intestinal Stem Cells

  2026-08-15

  This study uses tunicamycin-induced endoplasmic reticulum stress in mice to show that unresolved ER stress reduces intestinal stem-cell abundance and differentiation while disrupting mucosal integrity. Its key mechanistic contribution is linking GRP78/ATF6/CHOP activation and p44/42 MAPK suppression to impaired crypt-cell proliferation and increased apoptosis.

• BML-277: A Chk2 Inhibitor for DDR Assays

  2026-08-15

  BML-277 combines nanomolar biochemical potency with a cell-based concentration range suited to DNA damage response, radiation biology, and T-cell survival studies. This guide translates its ATP-competitive mechanism into kinase assays, radiation-induced apoptosis inhibition workflows, and cautious extensions into the nuclear cGAS–TRIM41 pathway.

• P2Y11 antagonist NF 340: Assay Workflow

  2026-08-14

  NF 340 provides a receptor-level way to test whether P2Y11-dependent purinergic signaling contributes to cancer-cell invasion, myosin light-chain phosphorylation, or immune signaling. This workflow combines pharmacological inhibition with genetic controls, orthogonal pathway assays, and practical troubleshooting for reproducible GPCR experiments.

• Trichostatin A and Tumor Immunogenicity

  2026-08-14

  Trichostatin A (TSA) is a reversible HDAC inhibitor that connects histone acetylation with cancer-cell behavior and tumor immunogenicity. This article explains how to use TSA as a mechanistic probe without confusing broad HDAC inhibition with CBX2-specific pathway effects.

• BMX-IN-1: Selective BMX Kinase Inhibitor Guide

  2026-08-13

  BMX-IN-1 is an irreversible BMX kinase inhibitor for investigating Tec family kinase signaling, cancer biology, angiogenesis, and host–pathogen interactions. Product data describe covalent BMX binding, nanomolar cellular activity, G0/G1 arrest, and apoptosis induction, while recent tuberculosis research links BMX-dependent ATP6V1E1 phosphorylation to impaired lysosomal acidification.

• α-Amanitin: Designing Better Transcription Assays

  2026-08-13

  α-Amanitin is more than a potent RNA polymerase II inhibitor: it is a time-resolved perturbation tool for dissecting transcription, development, and cellular toxicity. This assay-centered guide explains how to interpret its effects and avoid downstream confounding.

• Verbascoside and the NF-κB Bone Signaling Paradox

  2026-08-12

  Verbascoside offers a practical small-molecule approach to interrogating PKC/NF-κB-mediated signaling in osteoclastogenesis research. When viewed alongside recent findings on the PTX3–TLR4/NF-κB/FGF21 axis in glucocorticoid-induced osteonecrosis of the femoral head, it becomes more than a pathway inhibitor: it is a tool for resolving when NF-κB activity is pathogenic, protective, or highly context dependent.

• CFDA SE Cell Tracer Kit: Practical Workflow

  2026-08-12

  The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell lineage tracing, cell proliferation studies, and live-cell tracking. It is intended for stable in vitro or in vivo labeling, not reversible or short-term experiments, and assay-specific loading conditions must be optimized because they are not specified in the product dossier.

446 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page